MedPath

Yorkshire screening of urine trial (YORKSURe)

Not Applicable
Conditions
Bladder cancer
Cancer
Malignant neoplasm of bladder
Registration Number
ISRCTN34273159
Lead Sponsor
niversity of Sheffield
Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37678944/ (added 08/09/2023)

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
All
Target Recruitment
1311
Inclusion Criteria

Cohort 1:
1. Men and women
2. Aged 55 – 80 years
3. Participants already enrolled within the YLST
4. Registered with a GP within the Leeds CCG area
5. Consented to contact from other research teams at the second YLST Lung Health Check visit

Cohort 2:
1. Men aged 65-79 years
2. Registered with a GP Practice identified as being in a region with a high bladder cancer mortality risk

Cohort 3:
1. Men and women aged 65-79 years referred to a recruiting urological department under the 2WW pathway for the investigation of haematuria (to include cystoscopy and urinary tract ultrasound, ± CT urogram)

Exclusion Criteria

Current exclusion criteria as of 15/07/2022:
Cohort 1:
1. Unable to/did not consent to contact from other research teams
2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment.

Cohort 2:
1. National Data Opt-outs
2. Ever diagnosis of bladder or kidney cancer
3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer)
4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records:
4.1. Dementia
4.2. Alzheimer’s disease
4.3. Parkinson’s disease
or as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment

Cohort 3:
1. Unable to provide written informed consent
2. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions in medical notes:
2.1. Dementia
2.2. Alzheimer’s disease
2.3. Parkinson’s disease
or as determined by the investigator/person taking consent at the 2WW appointment
3. Evidence in patient medical record of historic dissent to use of data in research
4. Participant has opted out of data use via the National Data Opt Out

Previous exclusion criteria:
Cohort 1:
1. Unable to/did not consent to contact from other research teams
2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment.

Cohort 2:
1. National Data Opt-outs
2. Ever diagnosis of bladder or kidney cancer
3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer)
4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records:
4.1. Dementia
4.2. Alzheimer’s disease
4.3. Parkinson’s disease
or as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment

Cohort 3:
1. Unable to provide written informed consent
2. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions in medical notes:
2.1. Dementia
2.2. Alzheimer’s disease
2.3. Parkinson’s disease
or as determined by the investigator/person taking consent at the 2WW appointment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath